

1 **Title:** Machine Learning to Predict Mortality and Critical Events in COVID-19 Positive  
2 New York City Patients

3

4 **Short Title:** Predicting COVID-19 Outcomes With Machine Learning

5

6 **One-Sentence Summary:**

7 We identify clinical features that robustly predict mortality and critical events in a large  
8 cohort of COVID-19 positive patients in New York City.

9

10 **Authors:**

11 Akhil Vaid<sup>1</sup>, Sulaiman Somani<sup>1+</sup>, Adam J Russak<sup>1,2+</sup>, Jessica K De Freitas<sup>1,3</sup>, Fayzan F  
12 Chaudhry<sup>1,3</sup>, Ishan Paranjpe<sup>1</sup>, Kipp W Johnson<sup>3</sup>, Samuel J Lee<sup>1</sup>, Riccardo Miotto<sup>1,3</sup>,  
13 Shan Zhao<sup>1,4</sup>, Noam D Beckmann<sup>3</sup>, Nidhi Naik<sup>1</sup>, Kodi Arfer<sup>5</sup>, Arash Kia<sup>6,7</sup>, Prem  
14 Timsina<sup>6,7</sup>, Anuradha Lala<sup>6,8</sup>, Manish Paranjpe<sup>9</sup>, Patricia Glowe<sup>1</sup>, Eddy Golden<sup>1</sup>,  
15 Matteo Danieletto<sup>1</sup>, Manbir Singh<sup>1</sup>, Dara Meyer<sup>3</sup>, Paul F O'Reilly<sup>3,10,11</sup>, Laura H  
16 Huckins<sup>3,10,11</sup>, Patricia Kovatch<sup>12</sup>, Joseph Finkelstein<sup>6</sup>, Robert M Freeman<sup>6,7</sup>, Edgar  
17 Argulian<sup>13,14</sup>, Andrew Kasarskis<sup>3,6,15,16</sup>, Bethany Percha<sup>2</sup>, Judith A Aberg<sup>2,17</sup>, Emilia  
18 Bagiella<sup>7,8</sup>, Carol R Horowitz<sup>2,6</sup>, Barbara Murphy<sup>2</sup>, Eric J Nestler<sup>18,19</sup>, Eric E Schadt<sup>3,15</sup>,  
19 Judy H Cho<sup>20</sup>, Carlos Cordon-Cardo<sup>21</sup>, Valentin Fuster<sup>8,13,14</sup>, Dennis S Charney<sup>22</sup>, David  
20 L Reich<sup>4</sup>, Erwin P Bottinger<sup>1,2</sup>, Matthew A Levin<sup>4</sup>, Jagat Narula<sup>13,14</sup>, Zahi A Fayad<sup>23,24</sup>,  
21 Allan C Just<sup>5\*</sup>, Alexander W Charney<sup>3,10,11\*</sup>, Girish N Nadkarni<sup>1,2,18\*</sup>, Benjamin S  
22 Glicksberg<sup>1,3\*</sup> on behalf of the Mount Sinai Covid Informatics Center (MSCIC).

23

24 + Equal contribution

25 \*Co-correspondence

26

27 **Affiliations:**

- 28 1. The Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of  
29 Medicine at Mount Sinai
- 30 2. Department of Medicine, Icahn School of Medicine at Mount Sinai
- 31 3. Department of Genetics and Genomic Sciences, Icahn School of Medicine at  
32 Mount Sinai
- 33 4. Department of Anesthesiology, Perioperative and Pain Medicine, Icahn School of  
34 Medicine at Mount Sinai
- 35 5. Department of Environmental Medicine and Public Health, Icahn School of  
36 Medicine at Mount Sinai
- 37 6. Department of Population Health Science and Policy, Icahn School of Medicine  
38 at Mount Sinai
- 39 7. Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount  
40 Sinai

- 41 8. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of
- 42 Medicine at Mount Sinai
- 43 9. Harvard Medical School
- 44 10. The Pamela Sklar Division of Psychiatric Genomics, Icahn School of Medicine at
- 45 Mount Sinai
- 46 11. The Department of Psychiatry, Icahn School of Medicine at Mount Sinai
- 47 12. Mount Sinai Data Warehouse, Icahn School of Medicine at Mount Sinai
- 48 13. Mount Sinai Heart, Icahn School of Medicine at Mount Sinai
- 49 14. Department of Cardiology, Icahn School of Medicine at Mount Sinai
- 50 15. Icahn Institute for Data Science and Genomic Technology, Icahn School of
- 51 Medicine at Mount Sinai
- 52 16. Mount Sinai Data Office Icahn School of Medicine at Mount Sinai
- 53 17. Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai
- 54 18. Nash Family Department of Neuroscience, Icahn School of Medicine at Mount
- 55 Sinai
- 56 19. Friedman Brain Institute, Icahn School of Medicine at Mount Sinai
- 57 20. The Charles Bronfman Institute for Personalized Medicine, Icahn School of
- 58 Medicine at Mount Sinai
- 59 21. Department of Pathology, Icahn School of Medicine at Mount Sinai
- 60 22. Office of the Dean, Icahn School of Medicine at Mount Sinai
- 61 23. BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount
- 62 Sinai
- 63 24. Department of Radiology, Icahn School of Medicine at Mount Sinai

64  
65

66 Figures: 3

67 Tables: 1

68 Word Count: 3120

69

70 Correspondence:

71

72 Allan Just, PhD

73 [allan.just@mssm.edu](mailto:allan.just@mssm.edu)

74

75 Alexander Charney, MD, PhD

76 [alexander.charney@icahn.mssm.edu](mailto:alexander.charney@icahn.mssm.edu)

77

78 Girish Nadkarni, MD

79 [girish.nadkarni@mountsinai.org](mailto:girish.nadkarni@mountsinai.org)

80

81 Benjamin Glicksberg, PhD  
82 benjamin.glicksberg@mssm.edu  
83  
84

85 **Abstract**

86 Coronavirus 2019 (COVID-19), caused by the SARS-CoV-2 virus, has become the  
87 deadliest pandemic in modern history, reaching nearly every country worldwide and  
88 overwhelming healthcare institutions. As of April 20, there have been more than 2.4  
89 million confirmed cases with over 160,000 deaths. Extreme case surges coupled with  
90 challenges in forecasting the clinical course of affected patients have necessitated  
91 thoughtful resource allocation and early identification of high-risk patients. However,  
92 effective methods for achieving this are lacking. In this paper, we use electronic health  
93 records from over 3,055 New York City confirmed COVID-19 positive patients across  
94 five hospitals in the Mount Sinai Health System and present a decision tree-based  
95 machine learning model for predicting in-hospital mortality and critical events. This  
96 model is first trained on patients from a single hospital and then externally validated on  
97 patients from four other hospitals. We achieve strong performance, notably predicting  
98 mortality at 1 week with an AUC-ROC of 0.84. Finally, we establish model  
99 interpretability by calculating SHAP scores to identify decisive features, including age,  
100 inflammatory markers (procalcitonin and LDH), and coagulation parameters (PT, PTT,  
101 D-Dimer). To our knowledge, this is one of the first models with external validation to  
102 both predict outcomes in COVID-19 patients with strong validation performance and  
103 identify key contributors in outcome prediction that may assist clinicians in making  
104 effective patient management decisions.

105

106

## 107 **Introduction**

108 Despite substantial, organized efforts to prevent disease spread, over 2.4 million people  
109 have tested positive for SARS-CoV-2 worldwide, and there have been more than  
110 169,000 deaths to date (1–3). As a result of this pandemic, hospitals are being filled  
111 beyond capacity and face extreme challenges with regards to personnel staffing,  
112 personal protective equipment availability, and ICU bed allocation. Additionally, patients  
113 with COVID-19 demonstrate varying symptomatology, making successful and safe  
114 patient triaging difficult. While some infected patients are asymptomatic, others suffer  
115 from severe acute respiratory distress syndrome, multiorgan failure, and death (4).  
116 Identification of key patient characteristics that govern the course of disease across  
117 large patient cohorts is lacking but important, particularly given the potential it has to aid  
118 physicians and hospitals in predicting disease trajectory, to allocate essential resources  
119 effectively, and to improve patient outcomes. With these needs in mind, we report the  
120 development of a decision tree-based machine learning model trained on electronic  
121 health records from patients with confirmed COVID-19 status at a single center in the  
122 Mount Sinai Health System in New York City to predict critical events and mortality;  
123 validate this algorithm at four other hospital centers; and perform a saliency analysis  
124 using SHAP (SHapley Additive exPlanation) values to identify the most important  
125 features used by this model for outcome prediction.

126

## 127 **Results**

### 128 *Clinical Data Source and Study Population*

129 We retrieved electronic health records for 3,055 COVID-19-positive inpatient  
130 admissions at five hospitals between March 9, 2020 and April 11, 2020 within the Mount  
131 Sinai Health System (MSHS). These data included patient demographics, past medical  
132 history, and admission vitals and labs (Table 1, Supplementary Table 2). Relevant  
133 patient events (intubation, discharge to hospice care, or death) were recorded and  
134 subsets were constructed at 3, 5, 7, and 10 day intervals after admission (Figure 1). Of  
135 these patients, 17.0% to 31.6% had a critical event (intubation, discharge to hospice  
136 care, or death) and 6.0% to 21.5% died over the observed time frames (Supplementary  
137 Table 1). In contrast, the control group consisted of patients with all other discharge  
138 dispositions and those that were still hospitalized.

139

### 140 *Classifier training and performance*

141 Given the large number of patients in the analysis and presence of missing variables in  
142 the data, we used XGBoost (5), a boosted decision-tree based machine learning (ML)  
143 model, to predict either a critical event or death of a patient within the aforementioned  
144 time frames. Patients from the Mount Sinai Hospital (MSH) were split into a training and  
145 validation set for the model. To increase model generalizability and help minimize bias,  
146 the model's performance was assessed on a test set composed entirely of patients from

147 the other hospitals (OH) in the MSHS. While multiple time limits for event occurrence  
148 were assessed, the results and discussion in this letter focus predominantly one week  
149 after admission. As a control, both simple and generalized additive logistic regression  
150 models were trained to assess performance, given their ubiquity as the preferred model  
151 in current COVID research pieces.

152  
153 After training, the classifier robustly predicted the presence of a critical event at three,  
154 five, seven, and 10 days (Figure 2 and Supplementary Table 4) as measured by area  
155 under the receiver operating characteristic curve (AUC-ROC = 0.74 for OH, 0.83 for  
156 MSH at 1 week) and area under the precision-recall curve (AUPRC = 0.58 for OH, 0.49  
157 for MSH at 1 week). We were able to achieve similar performance at predicting critical  
158 events at longer intervals, namely 15 and 20 days (Supplementary Table 5). As a  
159 baseline comparison, the logistic regression models (Supplementary Table 6)  
160 performed more poorly in prediction by AUC-ROC (0.52 - 0.74) and AUC-PRC (0.19 -  
161 0.37) for critical events at three days relative to the XGBoost model (AUC-ROC = 0.77,  
162 AUC-PRC = 0.43). With respect to mortality, the model achieved high specificity (0.79 -  
163 0.92 for OH) and AUC-ROC (0.79 - 0.92 for OH) with similar AUPRC (0.38 - 0.65 OH)  
164 as with critical events. As the event time window increased, the performance of the  
165 classifier by the AUPRC value improved, which likely stems from the infrequency of  
166 deaths at earlier time points that created a class imbalance for mortality. Comparatively,  
167 all logistic regression models underperformed significantly in prediction by AUC-ROC  
168 (0.61-0.70) and AUC-PRC (0.06 - 0.18) for mortality.

169  
170 *Identifying important features in the model*

171 To identify the most salient features driving model prediction, SHAP (SHapley Additive  
172 exPlanations) values(6) were calculated for the highest-performing model in the cross-  
173 validation set during hyperparameter tuning (Figure 3). Among the top features, both  
174 high and low levels of lactate dehydrogenase (LDH), procalcitonin, and D-dimer were  
175 strong drivers for predicting a critical event at 1 week, while elevated prothrombin time  
176 (PT) and partial thromboplastin time (PTT) favored the classifier to predict a critical  
177 event. For mortality, both high and low values for age, procalcitonin, and red blood cell  
178 distribution width (RDW) were the strongest effectors in guiding mortality prediction by  
179 the model within 1 week of admission. Other important variables for increasing the  
180 prediction for death included an elevated troponin, LDH, lymphopenia (i.e. low  
181 lymphocyte percentage), white blood cell count (WBC), aspartate aminotransferase  
182 (AST), and D-dimer. Finally, using SHAP interaction scores, we discovered that  
183 covariate interactions between features, relative to each feature's independent  
184 importance, contributed less to the model's prediction (Supplementary Figures 1-4).

185  
186 **Discussion**

187 We highlight several important findings that have implications in clinical medicine. First,  
188 we offer robust prediction algorithms pertaining to the most clinically severe outcomes  
189 based solely on admission metrics. This insight provides the likely hospital course for  
190 patients up to 10 days into the future. High sensitivity in predicting mortality within three,  
191 five, and seven days of admission (0.86 - 1.0) suggests that this model can potentially  
192 be used by clinicians in gauging the acute clinical course of an admitted patient. The  
193 model's high specificity, particularly for mortality at days three (specificity = 0.92) and  
194 five (specificity = 0.86), suggest its role for augmenting clinicians' decision-making when  
195 identifying patients at immediate risk of impending clinical decompensation and  
196 potentially guide allocation of more intensive care upon admission.

197  
198 Additionally, our framework permits a clinically relevant understanding of the model's  
199 most salient features defining its decision boundaries. Age was the most important  
200 feature for mortality prediction in COVID-19+ patients, with a notable exponential rise of  
201 feature contribution as age increased (Figure 3)(7, 8). Elevations in serum LDH,  
202 although nonspecific markers of inflammation, are implicated in pulmonary endothelial  
203 cell injury and in COVID-19+ patients(9–11). Equivalently, procalcitonin has been  
204 implicated as a biomarker of underlying infection and sepsis risk(12, 13). Elevated  
205 RDW, which may be an index for enhanced patient frailty and risk of adverse  
206 outcomes(14), was also a strong driver of mortality. Other salient features like  
207 leukocytosis(15), a natural response to inflammation, in combination with virally-driven  
208 lymphopenia(16, 17), have also been associated with COVID-19 burden. Additionally,  
209 elevated troponins(18, 19), renal dysfunction from elevated creatinine(20), anemia, vital  
210 instability (low oxygen saturation, tachycardia, hypotension), elevated ferritin(10, 19),  
211 high lactate, and acidosis were also contributors to driving model prediction towards  
212 mortality. With growing evidence of COVID-19-induced hypercoagulable states in these  
213 patients(10, 21, 22), it is promising that our model recognized the feature importance of  
214 coagulability markers, such as PT, PTT, and D-dimer (Figure 3). Thus, this  
215 corroboration of the features learned by XGBoost and highlighted by the SHAP analysis  
216 with those findings from pathophysiological principles and more recent correlative  
217 studies exploring COVID-19 patients(2, 3, 18, 23–25) gives additional credibility to these  
218 findings.

219  
220 Just as interesting as the features present in the SHAP value analysis were those that  
221 were not. For example, because race is both poorly represented ("Unknown") and  
222 categorized inadequately in electronic health records, the model did not find race to be  
223 important for outcome prediction and instead opted to favor more objective data (vitals,  
224 labs). Contrary to our expectation, age was not identified as a significant feature for  
225 critical event prediction in these primary analyses. However, SHAP value analyses for  
226 critical event prediction at longer time frames (10, 15, and 20 days) revealed an



227 increasing importance on age for outcome prediction (Supplementary Figure 5). This  
228 trend suggests the model's decision to capture acute events by relying on more  
229 objective measures not confounded by other factors that are cached into age, which  
230 may better represent illness severity. However, over time, age may become a better  
231 marker for critical event prediction, by offering a more stable container of clinical  
232 information, given its invariance to change relative to other features. As such, the  
233 classifier becomes optimized for predicting severe events earlier in the course of illness.

234  
235 The results of our models should be considered in light of several limitations. First, we  
236 base our predictions solely on a patient's admission labs (i.e. within 36 hours); while this  
237 restriction encourages the use of this model in patient triage, events during a patient's  
238 hospital stay after admission may drive their clinical course away from the prior  
239 probability. Furthermore, not all patient labs are drawn at admission, which introduces  
240 an element of missingness in our dataset. For example, unlike the general patient  
241 population, patients on anticoagulation therapy, who likely have comorbidities  
242 increasing their baseline risk, will have coagulation labs (PT, PTT) taken on admission.  
243 However, the shift away from predicting death by the model in the absence of PT/PTT  
244 (Figure 3) suggests that missingness in coagulation labs is a proxy for this lower  
245 baseline risk secondary to not having comorbid conditions that require anticoagulation  
246 therapy. Additionally, patients admitted to the hospital later in the crisis were both  
247 beneficiaries of improved patient care protocols from experiential learning, but also  
248 victims of resource constraints from overburdened hospitals. These effects, while  
249 possibly negated by our large sample size, may also induce temporal variation between  
250 patient outcomes. Furthermore, inherent limitations exist when using EHRs, especially  
251 those integrated from multiple hospitals. In order to facilitate timely dissemination of our  
252 results, we chose not to manually chart review patient notes that may have otherwise  
253 provided additional potential features, such as symptoms and clinical course, to  
254 incorporate in our model. Because all five hospitals operate in a single health system,  
255 system-wide protocols in lab order sets and management protocols were an additional  
256 source of bias that may lower external validity. Other interhospital effects such as  
257 shuttling COVID-19 cases to certain hospitals for balancing systemic patient burden  
258 may also imbalance case severity across hospitals and care management between  
259 hospitals; certainly, this was the case for MSW, where mortality at 3-days was far lower  
260 (1.7%) than other hospital sites. This was ultimately a major reason to restrict model  
261 training to a single center and perform testing out of sample in another hospital center.  
262 Finally, though XGBoost is superior to other models at handling missing data, a notable  
263 drawback is its bias towards continuous features instead of categorical ones, given  
264 increased information represented in the form(28). However, collinearities between  
265 some categorical features in this dataset may be present with other continuous features,  
266 as exhibited by covariance strength between hypertension and systolic BP and



267 creatinine in Supplemental Figure 4, which can then serve as vehicles for capturing  
268 these categorical pieces of information.

269  
270 In conclusion, the COVID-19 pandemic unequivocally represents an unprecedented  
271 public health crisis. Healthcare institutions are facing extreme difficulties in managing  
272 resources and personnel. Physicians are treating record numbers of patients and  
273 continuously expose themselves to a highly contagious and virulent disease with  
274 varying symptomatology. Only few therapeutic options have demonstrated improvement  
275 to patient outcomes. As COVID-19 moves outside of the current epicenter in New York  
276 City, healthcare institutions will see a larger influx of affected patients and can benefit  
277 from immediate insights regarding assessment of disease severity(29, 30). These  
278 models successfully predict critical illness and mortality up to 10 days in advance in a  
279 diverse patient population from admission information alone and provide important  
280 markers for acute care prognosis that can be used by healthcare institutions to improve  
281 care decisions at both the physician and hospital level for management of COVID-19  
282 positive patients.

## 283 284 **Materials and Methods**

285  
286 This study has been approved by the Institutional Review Board at the Icahn School of  
287 Medicine at Mount Sinai (IRB- 20-03271).

### 288 289 *Clinical Data Source and Study Population*

290 In this study, patient data came from five hospitals within the Mount Sinai Hospital  
291 System (MSHS): the Mount Sinai Hospital (MSH) located in East Harlem, Manhattan;  
292 Mount Sinai Morningside (MSM) located in Morningside Heights, Manhattan; Mount  
293 Sinai West (MSW) located in Midtown and the West Side, Manhattan; Mount Sinai  
294 Brooklyn (MSB) located in Midwood, Brooklyn; and Mount Sinai Queens (MSQ) located  
295 in Astoria, Queens. The dataset was obtained from different sources and aggregated by  
296 the Mount Sinai COVID Informatics Center (MSCIC).

297  
298 We included patients who were over 18 years old that had a laboratory-confirmed  
299 COVID-19 infection, and were admitted between March 9 and April 11, 2020 to any of  
300 the hospitals previously mentioned. A confirmed case of COVID-19 was defined by a  
301 positive reverse transcriptase polymerase chain reaction (RT-PCR) assay of a  
302 nasopharyngeal swab. We excluded patients who had a positive COVID-19 RT-PCR  
303 result more than two days after admission. Additional exclusion criteria are presented in  
304 Figure 1. Full patient characteristics by site are provided in Supplementary Table 1.

### 305 306 *Study Data*

307 Demographics included age, sex, as well as reported race, and ethnicity. Race was  
308 collapsed into seven categories based off of the most recent US census race  
309 categories: American Indian or Alaskan Native, Asian, Black or African-American,  
310 Other, Native Hawaiian or Other Pacific Islander, Unknown, and White. Ethnicity was  
311 collapsed into three categories: Hispanic/Latino, Non-Hispanic/Latino, and Unknown.  
312 We obtained demographics, diagnosis codes (International Classification of Diseases-  
313 9/10-Clinical Modification (ICD-9/10-CM) codes and procedures), as well as vital signs  
314 and laboratory measurements during hospitalization. A pre-existing condition was  
315 defined as the presence of ICD-9/10-CM codes associated with specific diseases. We  
316 chose to include as covariates conditions that have been previously reported to have  
317 increased incidence in hospitalized COVID-19 patients, specifically: atrial fibrillation,  
318 asthma, cancer, coronary artery disease, chronic kidney disease, chronic obstructive  
319 pulmonary disease, diabetes mellitus, heart failure, hypertension, and stroke(15, 23–25,  
320 31).

321  
322 We included laboratory measurements and vital signs near the time of admission for  
323 prediction. Specifically, because records for laboratory values and vitals may appear  
324 with some lag, only the first available value within 36 hours of admission was included,  
325 otherwise the value was assigned as missing. Height was absent in a large percentage  
326 of the patients (18.2%). Because height is generally invariant in the adult population,  
327 and given the resource constraint of the pandemic, it was common for triage nurses to  
328 use the height from a previous and recent admission. In an effort to be as cohesive in  
329 our data gathering methods as possible, these earlier records were not retrieved for this  
330 dataset. However, weight was used as the next approximate proxy for body habitus,  
331 with additional information being presented through sex and age for body habitus as  
332 well.

333  
334 All lab orders from the five hospitals were queried for patients included in this study  
335 within the timeframe of interest. Due to discrepancies in how labs were named in  
336 different hospitals, a comprehensive review of all lab field names was conducted by a  
337 multidisciplinary team of clinical and statistical experts to ensure that there was a direct  
338 mapping between all sites. Additionally, many labs represented a single component  
339 (e.g. sodium), but were acquired from either an arterial blood gas (ABG), venous blood  
340 gas (VBG), and basic metabolic panel (BMP). Based on the utility of these lab values in  
341 clinical practice and the similarity between their statistical distributions, labs derived  
342 from a VBG or BMP were collapsed into a single category (i.e. 'SODIUM') and those  
343 derived from an ABG were moved to a separate category (i.e. 'SODIUM\_A'). Finally, the  
344 earliest lab, by time of result, in the set of all lab order names that were combined into a  
345 single lab category was chosen as the representative lab value for that category.  
346 Finally, lab data below the 0.5th and above the 99.5th percentiles were removed to

347 avoid inclusion of any obvious outliers that could represent incorrect documentation and  
348 measurement error.

349

### 350 *Definition of Outcomes*

351 The two primary outcomes were 1) death versus survival or discharge, and 2) critical  
352 illness versus survival or discharge, through time horizons of 3, 5, 7, and 10 days.

353 Critical illness is defined as discharge to hospice, intubation  $\leq$  48 hours prior to ICU  
354 admission, or death. To address potential concerns of censoring by limiting exploration  
355 of only these time frames, particularly in the case of model enrichment for acute critical  
356 events, we also predicted critical events at days 15 and 20.

357

### 358 *Statistical Analysis*

359 Our primary model was fit with the Extreme Gradient Boosting (XGBoost)  
360 implementation of boosted decision trees on continuous and one-hot encoded  
361 categorical features. The XGBoost algorithm provides state-of-the-art prediction results  
362 through an iterative process of averaging in decision trees (we used 100) fit to the  
363 residual error of the prior ensemble. While each tree is too simple to accurately capture  
364 complex phenomena, the combination of many trees in the XGBoost model  
365 accommodates non-linearity and interactions between predictors. Missing data values  
366 are routed through split points based on the direction to minimize loss. XGBoost models  
367 were trained and evaluated using 10-fold stratified cross validation. For each fold,  
368 hyperparameter tuning was performed by randomized grid searching directed towards  
369 maximizing the sensitivity metric over 2,000 discrete grid options. Cross-validation was  
370 performed inside each grid option. We present the model hyperparameters for all  
371 experiments in Supplementary Table 3. The performance of the models were measured  
372 using the area under the receiver operator characteristic curve (AUC-ROC), area under  
373 the precision-recall curve (AUC-PRC), F1-score, sensitivity, and specificity. To interpret  
374 the significance of input features on the model's prediction, SHAP values across all  
375 features on the best-performing model, by AUC-ROC, in the cross-validation set were  
376 calculated. Finally, we tested these models built on patient data from MSH on patients  
377 from four other hospitals (Figure 1).

378

379 As a baseline, we also fit a logistic regression model and a generalized additive logistic  
380 model to compare our XGBoost model. We decided to use a generalized additive model  
381 because of its ability to extend generalized linear models by allowing for non-linear  
382 functions of features. Four main models were generated: 1) Logistic regression using  
383 only Age 2) Generalized Additive Model using only Age 3) Logistic Regression with all  
384 available features 4) Generalized Additive Model using all available features. Since

385 these models do not have a built in method of dealing with missing data, we dropped  
386 features with over 70% missingness and samples that lacked values for the remaining  
387 feature space. The models were trained and evaluated using 10-fold stratified cross  
388 validation on patient data from MSH and subsequently evaluated on patient data from  
389 the other hospitals. The same metrics were recorded for these models; however, this  
390 model was only trained at outcome prediction on Day 3, which was the time frame at  
391 which model AUC-ROC was highest for the XGBoost classifier. Performance results for  
392 this classifier are represented in Supplementary Table 5.


## 393 References

- 394 1. G. Onder, G. Rezza, S. Brusaferro, Case-Fatality Rate and Characteristics of  
395 Patients Dying in Relation to COVID-19 in Italy *JAMA* (2020),  
396 doi:10.1001/jama.2020.4683.
- 397 2. W.-J. Guan, Z.-Y. Ni, Y. Hu, W.-H. Liang, C.-Q. Ou, J.-X. He, L. Liu, H. Shan, C.-L.  
398 Lei, D. S. C. Hui, B. Du, L.-J. Li, G. Zeng, K.-Y. Yuen, R.-C. Chen, C.-L. Tang, T. Wang,  
399 P.-Y. Chen, J. Xiang, S.-Y. Li, J.-L. Wang, Z.-J. Liang, Y.-X. Peng, L. Wei, Y. Liu, Y.-H.  
400 Hu, P. Peng, J.-M. Wang, J.-Y. Liu, Z. Chen, G. Li, Z.-J. Zheng, S.-Q. Qiu, J. Luo, C.-J.  
401 Ye, S.-Y. Zhu, N.-S. Zhong, China Medical Treatment Expert Group for Covid-19,  
402 Clinical Characteristics of Coronavirus Disease 2019 in China, *N. Engl. J. Med.* (2020),  
403 doi:10.1056/NEJMoa2002032.
- 404 3. E. Livingston, K. Bucher, Coronavirus Disease 2019 (COVID-19) in Italy *JAMA* **323**,  
405 1335 (2020).
- 406 4. K. Mizumoto, K. Kagaya, A. Zarebski, G. Chowell, Estimating the asymptomatic  
407 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond  
408 Princess cruise ship, Yokohama, Japan, 2020, *Eurosurveillance* **25**, 2000180 (2020).
- 409 5. T. Chen, C. Guestrin, XGBoost: A Scalable Tree Boosting System (2016),  
410 doi:10.1145/2939672.2939785.
- 411 6. S. M. Lundberg, S.-I. Lee, in *Advances in Neural Information Processing Systems*,  
412 (2017), pp. 4765–4774.
- 413 7. K. Wang, P.-Y. Zuo, Y. Liu, M. Zhang, X. Zhao, S. Xie, H. Zhang, X. Chen, C. Liu,  
414 Clinical and Laboratory Predictors of In-Hospital Mortality in 305 Patients with COVID-  
415 19: A Cohort Study in Wuhan, China, (2020), doi:10.2139/ssrn.3546115.
- 416 8. Q. Ruan, K. Yang, W. Wang, L. Jiang, J. Song, Clinical predictors of mortality due to  
417 COVID-19 based on an analysis of data of 150 patients from Wuhan, China, *Intensive*  
418 *Care Med.* , 1–3 (2020).
- 419 9. M. Drent, N. A. Cobben, R. F. Henderson, E. F. Wouters, M. van Dieijen-Visser,  
420 Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage  
421 or inflammation, *Eur. Respir. J.* **9**, 1736–1742 (1996).
- 422 10. E. Terpos, I. Ntanasias-Stathopoulos, I. Elalamy, E. Kastritis, T. N. Sergentanis, M.  
423 Politou, T. Psaltopoulou, G. Gerotziafas, M. A. Dimopoulos, Hematological findings and  
424 complications of COVID-19, *Am. J. Hematol.* (2020), doi:10.1002/ajh.25829.
- 425 11. B. M. Henry, M. H. S. de Oliveira, S. Benoit, M. Plebani, G. Lippi, Hematologic,  
426 biochemical and immune biomarker abnormalities associated with severe illness and  
427 mortality in coronavirus disease 2019 (COVID-19): a meta-analysis, *Clin. Chem. Lab.*  
428 *Med.* (2020), doi:10.1515/cclm-2020-0369.

- 429 12. A. L. Vijayan, Vanimaya, S. Ravindran, R. Saikant, S. Lakshmi, R. Kartik, M. G,  
430 Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy, *J.*  
431 *Intensive Care Med.* **5**, 51 (2017).
- 432 13. J. T. Poston, B. K. Patel, A. M. Davis, Management of Critically Ill Adults With  
433 COVID-19, *JAMA* (2020), doi:10.1001/jama.2020.4914.
- 434 14. C. Fava, F. Cattazzo, Z.-D. Hu, G. Lippi, M. Montagnana, The role of red blood cell  
435 distribution width (RDW) in cardiovascular risk assessment: useful or hype?, *Ann Transl*  
436 *Med* **7**, 581 (2019).
- 437 15. J. Zhu, P. Ji, J. Pang, Z. Zhong, H. Li, C. He, J. Zhang, C. Zhao, Clinical  
438 characteristics of 3,062 COVID-19 patients: a meta-analysis, *J. Med. Virol.* (2020),  
439 doi:10.1002/jmv.25884.
- 440 16. J. Liu, H. Li, M. Luo, J. Liu, L. Wu, X. Lin, R. Li, Z. Wang, H. Zhong, W. Zheng, Y.  
441 Zhou, D. Jiang, X. Tan, Z. Zhou, H. Peng, G. Zhang, Lymphopenia acted as an adverse  
442 factor for severity in patients with COVID-19: a single-centered, retrospective study *In*  
443 *Review* (2020).
- 444 17. L. Tan, Q. Wang, D. Zhang, J. Ding, Q. Huang, Y.-Q. Tang, Q. Wang, H. Miao,  
445 Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study,  
446 *Signal Transduct Target Ther* **5**, 33 (2020).
- 447 18. S. Shi, M. Qin, B. Shen, Y. Cai, T. Liu, F. Yang, W. Gong, X. Liu, J. Liang, Q. Zhao,  
448 H. Huang, B. Yang, C. Huang, Association of Cardiac Injury With Mortality in  
449 Hospitalized Patients With COVID-19 in Wuhan, China, *JAMA Cardiol* (2020),  
450 doi:10.1001/jamacardio.2020.0950.
- 451 19. A. N. Kochi, A. P. Tagliari, G. B. Forleo, G. M. Fassini, C. Tondo, Cardiac and  
452 arrhythmic complications in patients with COVID-19, *J. Cardiovasc. Electrophysiol.*  
453 (2020), doi:10.1111/jce.14479.
- 454 20. Y. Cheng, R. Luo, K. Wang, M. Zhang, Z. Wang, L. Dong, J. Li, Y. Yao, S. Ge, G.  
455 Xu, Kidney disease is associated with in-hospital death of patients with COVID-19,  
456 *Kidney Int.* (2020), doi:10.1016/j.kint.2020.03.005.
- 457 21. Y. Zhang, M. Xiao, S. Zhang, P. Xia, W. Cao, W. Jiang, H. Chen, X. Ding, H. Zhao,  
458 H. Zhang, C. Wang, J. Zhao, X. Sun, R. Tian, W. Wu, D. Wu, J. Ma, Y. Chen, D. Zhang,  
459 J. Xie, X. Yan, X. Zhou, Z. Liu, J. Wang, B. Du, Y. Qin, P. Gao, X. Qin, Y. Xu, W. Zhang,  
460 T. Li, F. Zhang, Y. Zhao, Y. Li, S. Zhang, Coagulopathy and Antiphospholipid Antibodies  
461 in Patients with Covid-19, *N. Engl. J. Med.* (2020), doi:10.1056/NEJMc2007575.
- 462 22. F. A. Klok, M. J. H. A. Kruip, N. J. M. van der Meer, M. S. Arbous, D. A. M. P. J.  
463 Gommers, K. M. Kant, F. H. J. Kaptein, J. van Paassen, M. A. M. Stals, M. V. Huisman,  
464 H. Endeman, Incidence of thrombotic complications in critically ill ICU patients with  
465 COVID-19, *Thromb. Res.* (2020), doi:10.1016/j.thromres.2020.04.013.




- 466 23. Y. Liu, Y. Yang, C. Zhang, F. Huang, F. Wang, J. Yuan, Z. Wang, J. Li, J. Li, C.  
467 Feng, Z. Zhang, L. Wang, L. Peng, L. Chen, Y. Qin, D. Zhao, S. Tan, L. Yin, J. Xu, C.  
468 Zhou, C. Jiang, L. Liu, Clinical and biochemical indexes from 2019-nCoV infected  
469 patients linked to viral loads and lung injury, *Sci. China Life Sci.* **63**, 364–374 (2020).
- 470 24. L. Wynants, B. Van Calster, M. M. J. Bonten, G. S. Collins, T. P. A. Debray, M. De  
471 Vos, M. C. Haller, G. Heinze, K. G. M. Moons, R. D. Riley, E. Schuit, L. J. M. Smits, K. I.  
472 E. Snell, E. W. Steyerberg, C. Wallisch, M. van Smeden, Prediction models for  
473 diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal,  
474 *BMJ* **369** (2020), doi:10.1136/bmj.m1328.
- 475 25. J. Gong, J. Ou, X. Qiu, Y. Jie, Y. Chen, L. Yuan, J. Cao, M. Tan, W. Xu, F. Zheng,  
476 Y. Shi, B. Hu, A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) :  
477 A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China, *Clin.*  
478 *Infect. Dis.* (2020), doi:10.1093/cid/ciaa443.
- 479 26. R. Witzig, The medicalization of race: scientific legitimization of a flawed social  
480 construct, *Ann. Intern. Med.* **125**, 675–679 (1996).
- 481 27. L. M. Hunt, N. D. Truesdell, M. J. Kreiner, Genes, race, and culture in clinical care:  
482 racial profiling in the management of chronic illness, *Med. Anthropol. Q.* **27**, 253–271  
483 (2013).
- 484 28. C. Strobl, A.-L. Boulesteix, A. Zeileis, T. Hothorn, Bias in random forest variable  
485 importance measures: illustrations, sources and a solution, *BMC Bioinformatics* **8**, 25  
486 (2007).
- 487 29. K. F. Boreskie, P. E. Boreskie, D. Melady, Age is just a number - and so is frailty:  
488 Strategies to inform resource allocation during the COVID-19 pandemic, *CJEM*, 1–3  
489 (2020).
- 490 30. A. J. Singer, E. J. Morley, M. C. Henry, Staying Ahead of the Wave, *N. Engl. J. Med.*  
491 (2020), doi:10.1056/NEJMc2009409.
- 492 31. H. M. Alger, J. H. Williams Iv, J. G. Walchok, M. M. Bolles, G. C. Fonarow, C.  
493 Rutan, The Role of Data Registries in the Time of COVID-19, *Circ. Cardiovasc. Qual.*  
494 *Outcomes* (2020), doi:10.1161/CIRCOUTCOMES.120.006766.



495  
496  
497  
498  
499  
500  
501  
502

**Fig 1. Study Design and Workflow.**

**A)** Procedure for patient inclusion in our study. **B)** Strategy and design for experiments. Patient clinical data from Mount Sinai Hospital (MSH) was used to train and validate our machine learning model. We then test these models on patients from four other external hospitals within the Mount Sinai Health System: Mount Sinai Brooklyn (MSB), Mount Sinai Morningside (MSM), Mount Sinai Queens (MSQ), and Mount Sinai West (MSW). **C)** Machine learning experimental design. We train on data from admission to predict mortality and critical illness outcomes.




503

504

505 **Fig 2. Machine learning experimental results.**

506 In all plots, the orange line reflects training at Mount Sinai Hospital (MSH) and testing  
507 via cross-validation. The blue line reflects testing the model built on patient data from  
508 MSH on external patients from all other hospitals (OH) **A**) Area under the receiver  
509 operator characteristic curve (AUC-ROC) for predicting critical illness at seven days  
510 since admission. **B**) Area under the precision-recall curves (AUPRC) for predicting  
511 critical illness at seven days since admission. **C**) AUC for predicting mortality at seven  
512 days since admission. **D**) AUPRC for predicting critical illness at seven days since  
513 admission.

515  
516517 **Fig 3. SHAP Summary and Dependency Plots.**

518 SHAP summary plots for critical event **(A)** and mortality **(D)** at 7 days show the SHAP values for the most important  
 519 features for the respective XGBoost model. Features in the summary plots (y-axis) are organized by their mean absolute  
 520 SHAP values (x-axis), which represents the importance of that feature in driving the classifier's prediction, for patients.  
 521 Values of those features for each patient (i.e. a particular LDH value) are colored by their relative value. **(B)** and **(C)**  
 522 represent dependency plots, which similarly demonstrate how different values of those features can affect the SHAP  
 523 score and ultimately impact classifier decisions, for prothrombin time (PT) and D-Dimer, respectively, for critical event  
 524 prediction. **(E)** and **(F)** represent dependency plots for age and procalcitonin levels. Patients with missing values for a  
 525 feature in the dependency plot are clustered in the shaded area to the left.


526 **Table 1.** Characteristics of Hospitalized Covid-19 Patients at Baseline (n= 3055)  
527

<b>Characteristics of Admission</b>	<b>MSH</b>	<b>Other locations</b>
<b>Demographics</b>		
<b>Sex, n (%)</b>		
Male	704 (57.5)	1070 (58.5)
Female	521 (42.5)	760 (41.5)
<b>Race, n (%)</b>		
Other	537 (43.8)	749 (40.9)
Caucasian	293 (23.9)	435 (23.8)
African American	273 (22.3)	503 (27.5)
Unknown	64 (5.2)	60 (3.3)
Asian	44 (3.6)	65 (3.5)
Pacific Islander	14 (1.1)	18 (0.9)
<b>Ethnicity, n (%)</b>		
Non-Hispanic Latino	676 (55.2)	1133 (61.9)
Hispanic/Latino	333 (27.2)	503 (27.5)
Unknown	216 (17.6)	194 (10.6)
<b>Age, Median (IQR)</b>	<b>62.1 (49.4-71.8)</b>	<b>68.33 (56.9-78.8)</b>
<b>Age group, n (%)</b>		
18-30	56 (4.6)	37 (2.0)
31-40	139 (11.6)	93 (5.1)
41-50	133 (10.9)	158 (8.6)
51-60	242 (19.8)	309 (16.9)
61-70	320 (26.1)	431 (23.5)
71-80	202 (16.5)	422 (23.1)
81-90	102 (8.3)	308 (16.8)
At least 90	31 (2.5)	72 (3.9)
<b>Previous Medical History, n (%)</b>		
Hypertension (%)	462 (37.7)	686 (37.5)
Atrial Fibrillation (%)	86 (7.0)	130 (7.1)
Coronary Artery Disease (%)	171 (13.9)	307 (16.8)
Heart failure (%)	110 (8.9)	181 (9.9)
Stroke (%)	98 (8)	118 (6.5)

Chronic Kidney Disease (%)	136 (11.1)	158 (8.6)
Diabetes (%)	313 (25.5)	466 (25.5)
Asthma (%)	115 (9.4)	132 (7.2)
Chronic Obstructive Pulmonary Disease (%)	65 (5.3)	103 (5.6)
Cancer (%)	112 (9.1)	94 (5.1)
<b>Vital Signs at Hospital Admission, Median (IQR)</b>		
Heart Rate (bpm)	89 (78 -100)	89 (78 - 100)
Pulse Oximetry (%)	96 (94 - 98)	96 (94 - 98)
Respiration Rate (breaths / minute)	20 (18 - 20)	18 (18 - 20)
Temperature (F)	98.7 (98.1 - 99.9)	97.9 (98.6 - 99.5)
Systolic Blood Pressure (mmHg)	124 (112 - 138)	127 (112 - 142)
Diastolic Blood Pressure (mmHg)	69 (61 - 78)	72 (65 - 81)
Weight (kg)	80.9 (68.9 - 95.3)	78.9 (68.04 - 91.7)
<b>Admission Laboratory Parameters, Median (IQR)</b>		
<b>Metabolic markers</b>		
Sodium (mEq/L)	137 (135 - 140)	138 (135 -141)
Potassium (mEq/L)	4 (3.6 - 4.5)	4.2 (3.9 - 4.7)
Creatinine (mg/dL)	0.9 (0.7 - 1.4)	1.0 (0.8 -1.6)
Lactate (mg/dL)	1.7 (1.3 - 2.2)	1.4 (1.1 - 2.0)
<b>Hematological markers</b>		
White Blood Cells ( $10^3/\mu\text{L}$ )	6.8 (5.2 - 9.8)	7.7 (5.7 - 10.5)
Lymphocyte Percentage	13.1 (7.8 - 20.7)	14.1 (8.9 - 21.4)
Hemoglobin (mEq/L)	12.5 (11.1 - 13.7)	12.8 (11.4 - 14)
Red Blood Cell Distribution Width (%)	14.4 (13.6 -15.6)	12.7 (12.1 - 13.9)
Platelets (#)	212 (162 - 279.3)	194 (148 - 260)
<b>Liver Function</b>		
Alanine Aminotransferase (units/L)	31 (19 - 54)	31 (20 - 53)
Aspartate Aminotransferase (units/L)	41.5 (29 - 67)	47 (31 - 74)
Albumin (g/dL)	3 (2.6 - 3.3)	3 (2.6 - 3.3)
Total Bilirubin (mg/dL)	0.6 (0.4 - 0.8)	0.6 (0.4 - 0.8)
<b>Coagulation markers</b>		
Prothrombin Time (s)	14.3 (13.5 - 15.7)	14.2 (13.5 - 15.5)
Partial Thromboplastin Time (s)	32.5 (29.2 - 37.1)	33.3 (30 - 38.8)



<b>Gases</b>		
PCO <sub>2</sub> (mmHg)	37 (41 - 47)	41 (35 - 47)
pH	7.4 (7.4 - 7.4)	7.4 (7.3 - 7.4)
<b>Inflammatory markers</b>		
C Reactive Protein (mg/L)	152.3 (83.1 - 205.6)	124.6 (62.3 - 214.5)
Ferritin (ng/mL)	720 (343.5 - 1813.8)	818 (388 - 1966)
D-Dimer (ng/mL)	1.3 (0.7 - 2.5)	1.5 (0.9 - 3.0)
Creatinine Phosphokinase (units/L)	156 (80 - 505)	237.5 (187.8 - 440.5)
Lactate Dehydrogenase (units/L)	417 (315 - 559)	450 (346.3 - 610.8)
Procalcitonin (ng/mL)	0.2 (0.1 - 0.6)	0.2(0.1 - 0.7)
<b>Cardiac markers</b>		
Troponin I (ng/mL)	0.1 (0.02 - 0.2)	0.2 (0.1- 0.9)




529

530

531 **Supplementary Fig 1. SHAP Interactions: Critical Event at 7 Days.**

532 Heatmap demonstrating the composite SHAP interaction scores between features for patients from the best performing k-  
 533 th validation fold for critical event prediction at 7 days. The intensity along the diagonal represents independent  
 534 contributions of a feature towards model prediction (i.e. mean absolute SHAP values in Figure 3). Covariant interactions  
 535 between features is significantly less relative to the intensity of the independent contributions of each feature towards  
 536 model prediction.




537

538

539 **Supplementary Fig 2. SHAP Interactions: Critical Event at 7 Days (Univariate Effect Removal).**


540 Heatmap demonstrating the composite SHAP interaction scores between features for patients from the best performing k-  
 541 th validation fold for critical event prediction at 7 days. Univariate feature contributions along the diagonal have been set to  
 542 0 to better examine the relative strength of covariance between features.



543  
544  
545  
546  
547  
548  
549  
550

**Supplementary Fig 3. SHAP Interactions: Mortality at 7 Days.**

Heatmap demonstrating the composite SHAP interaction scores between features for patients from the best performing k-th validation fold for mortality prediction at 7 days. The intensity along the diagonal represents independent contributions of a feature towards model prediction (i.e. mean absolute SHAP values in Figure 3). Covariant interactions between features is significantly less relative to the intensity of the independent contributions of each feature towards model prediction.




551

552

553 **Supplementary Fig 4. SHAP Interactions: Mortality at 7 Days (Univariate Effect Removal).**

554 Description: Heatmap demonstrating the composite SHAP interaction scores between features for patients from the best  
 555 performing k-th validation fold for mortality prediction at 7 days. Univariate feature contributions along the diagonal have  
 556 been set to 0 to better examine the relative strength of covariance between features.



557

558 **Supplementary Fig 5. Importance of Age Over Time Frames**

559 Mean absolute SHAP value for age (blue) to represent importance in prediction of critical event occurrence over different  
560 time frames (7, 10, 15, and 20 days).



561 **Supplementary Table 1. Baseline Patient Characteristics by Hospital.**

562 Characteristics, such demographics, clinical history, vital signs, and laboratory tests, for  
 563 all patients included in the study and delineated by the hospital site at which the patient  
 564 was admitted.

565

Characteristics or Admission	MSQ	MSB	MSH	MSW	MSM
<b>Demographics</b>					
<b>Sex, n (%)</b>					
Male	291 (63.4)	207 (58.9)	317 (56.6)	255 (55.4)	704 (57.47)
Female	168 (36.6)	144 (41.0)	243 (43.4)	205 (44.6)	521 (42.53)
<b>Race, n (%)</b>					
Other	33 (7.2)	9 (1.9)	44 (3.6)	16 (4.6)	7 (1.3)
African American	50 (10.9)	191 (41.5)	273 (22.3)	68 (19.4)	194 (34.6)
Caucasian	264 (57.5)	91 (19.8)	537 (43.8)	131 (37.3)	263 (46.9)
Asian	9 (1.9)	0 (0)	14 (1.1)	4 (1.1)	5 (0.9)
Pacific Islander	16 (3.5)	19 (4.1)	64 (5.2)	5 (1.4)	20 (3.6)
Unknown	87 (18.9)	150 (32.6)	293 (23.9)	127 (36.2)	71 (12.7)
<b>Ethnicity, n (%)</b>					
Hispanic/Latino	230 (50.1)	322 (70)	676 (55.2)	251 (71.5)	330 (58.9)
Non-Hispanic Latino	188 (40.9)	17 (3.7)	333 (27.2)	92 (26.2)	206 (36.8)
Unknown	41 (8.9)	121 (26.3)	216 (17.6)	8 (2.3)	24 (4.3)
<b>Age - Median(IQR)</b>	66 (56-77)	65.3 (51.7-76.4)	68.8 (56.0-80.1)	72 (63-82)	62.1 (49.4-71.8)
<b>Age group, n (%)</b>					
18-30	10 (2.2)	16 (4.6)	7 (1.3)	4 (0.9)	56 (4.6)
31-40	16 (3.5)	38 (10.8)	32 (5.7)	7 (1.5)	139 (11.4)
41-50	49 (10.7)	32 (9.1)	60 (10.7)	17 (3.7)	133 (10.9)
51-60	92 (20.0)	62 (17.7)	90 (16.1)	65 (14.1)	242 (19.8)
61-70	110 (23.9)	71 (20.2)	123 (21.9)	127 (27.6)	320 (26.1)
71-80	108 (23.5)	73 (20.8)	120 (21.4)	121 (26.3)	202 (16.5)
81-90	64 (13.9)	51 (14.5)	101 (18.0)	92 (20)	102 (8.3)
At least 90	10 (2.2)	8 (2.3)	27 (4.8)	27 (5.9)	31 (2.5)
<b>Previous Medical History, n (%)</b>					
Hypertension (%)	228 (49.7)	120 (34.2)	210 (37.5)	128 (27.8)	462 (37.7)

Atrial Fibrillation (%)	45 (9.8)	18 (5.1)	40 (7.1)	27 (5.9)	86 (7.0)
Coronary Artery Disease (%)	95 (20.7)	46 (13.1)	85 (15.2)	81 (17.6)	171 (13.9)
Heart failure (%)	51 (11.1)	27 (7.7)	61 (10.9)	42 (9.1)	110 (8.9)
Stroke (%)	43 (9.4)	22 (6.3)	39 (6.9)	14 (3.0)	98 (8)
Chronic Kidney Disease (%)	54 (11.8)	20 (5.7)	58 (10.4)	26 (5.6)	136 (11.1)
Diabetes (%)	154 (33.6)	68 (19.4)	143 (25.5)	101 (21.9)	313 (25.6)
Asthma (%)	42 (9.2)	32 (9.1)	45 (8.0)	13 (2.8)	115 (9.4)
Chronic Obstructive Pulmonary Disease (%)	35 (7.6)	16 (4.6)	31 (5.5)	21 (4.6)	65 (5.1)
Cancer (%)	20 (4.4)	30 (8.5)	33 (5.9)	11 (2.4)	112 (9.1)
<b>Vital Signs at Hospital Admission, Median (IQR)</b>					
Heart Rate (bpm)	89 (78 – 101)	89 (78-100.2)	89 (78-100)	85 (76-96)	89 (79-101.3)
Oxygen Saturation (%)	95 (93-97)	96 (94-98)	96 (94-98)	96 (94.5-98)	96 (94-98)
Respiration Rate (breaths / minute)	18 (18-20)	18 (18-19.3)	20 (18-22)	18 (17- 20)	20 (18-22)
Temperature (F)	98.8 (98.2-99.7)	98 (97.3-98.7)	98.7 (98.1-99.9)	98.7 (98-99.6)	99 (98.2-100)
Systolic Blood Pressure (mmHg)	70 (63-78)	70 (62.75-80)	69 (61-78)	74 (65.5-84)	74 (66.8-82)
Diastolic Blood Pressure (mmHg)	123 (110-138)	130 (112-145)	124 (112-138)	126 (111-137)	128.5 (114-144)
Weight (kg)	76.3 (65.2-90.7)	79.4 (68.1-92.9)	80.9 (69.0-95.3)	78.8 (67.6-90.7)	79.6 (69.1-92.2)
<b>Admission Laboratory Parameters, Median (IQR)</b>					
<b>Metabolic Markers</b>					
Sodium (mEq/L)	138 (136-141)	139 (137-142)	137 (135-140)	137 (134-139)	138 (135-141)
Potassium (mEq/L)	4.3 (3.9-4.7)	4.3 (3.8-4.7)	4 (3.6-4.5)	4.2 (3.9-4.7)	4.2 (3.8-4.7)
Creatinine (mg/dL)	1 (0.8-2.1)	1.2 (0.9-2.1)	0.9 (0.7-1.4)	0.9 (0.7-1.3)	1.0 (0.8-1.7)
Lactate (mg/dL)	-	1.94 (1.1-2.9)	1.7 (1.3-2.2)	1.5 (1.1-2)	1.3 (1-1.8)
<b>Hematological Markers</b>					
White Blood Cells (103/ $\mu$ L)	7.9 (5.9-10.5)	7.5 (5.4-10.5)	6.8 (5.2-9.8)	7.7 (5.6-10.9)	7.5 (5.7-10.5)
Lymphocyte Percentage	12 (7.1-18.3)	14.7 (8.9-22.7)	13.1 (7.8-20.1)	16.1 (9.6-23.1)	13.05 (9-20.5)
Hemoglobin (mEq/L)	12.6 (11.1-13.8)	12.5 (11.2-13.8)	12.5 (11.1-13.7)	13 (11.6-14.2)	13 (11.6-14)

Red Blood Cell Distribution Width (%)	12.8 (12.1-14.2)	13.1 (12.5-14.1)	14.4 (13.6-15.6)	12.5 (12-13.5)	12.6 (12.1-13.7)
Platelets (#)	188 (146-259)	205.5 (153-266.2)	212 (162-279.3)	197 (152-264)	187 (144-252)
<b>Liver Function</b>					
Alanine Aminotransferase (units/L)	34 (21-55)	28 (19-49)	31 (19-54)	30 (19-54)	32 (19-54.8)
Aspartate Aminotransferase (units/L)	50 (34-76.8)	42 (28-74)	41.5 (29-67)	48.5 (32-77)	45 (31-71)
Albumin (g/dL)	2.7 (2.3-3.2)	3.4 (3.1-3.7)	3 (2.6-3.3)	3 (2.6-3.3)	2.9 (2.5-3.1)
Total Bilirubin (mg/dL)	0.6 (0.4-0.7)	0.6 (0.4-0.7)	0.6 (0.4-0.8)	0.5 (0.4-0.8)	0.6 (0.4-0.8)
<b>Coagulation Markers</b>					
Prothrombin Time (s)	14 (13.4-17.2)	14.6 (13.5-16.1)	14.3 (13.5-15.7)	13.9 (13.4-14.9)	14.2 (13.6-15.3)
Partial Thromboplastin Time (s)	35.7 (32.2-61.2)	35.2 (32.3-38.6)	32.5 (29.2-37.2)	32.1 (29.8-37.5)	32.9 (29.4-38.7)
<b>Gases</b>					
PCO2 (mmHg)	-	40 (34.3-46)	41 (37-47)	41.5 (36.3-48)	41 (35-47)
pH	-	7.4 (7.3-7.4)	7.4 (7.4-7.4)	7.4 (7.3-7.4)	7.4 (7.3-7.4)
<b>Inflammatory Markers</b>					
C Reactive Protein (mg/L)	207.2 (159.4-233.4)	147.7 (90.7-243.3)	152.3 (83.1-205.6)	104.9 (50.6-190.4)	125.4 (62.7-201.6)
Ferritin (ng/mL)	968 (473.6-2378.3)	999.5 (522.2-2228.5)	720 (343.5-1813.8)	713.5 (305.8-1466)	763 (360- 1784)
D-Dimer (ng/mL)	1.5 (1.0-2.9)	2.3 (1.1-4.1)	1.3 (0.7-2.5)	1.4 (0.7-2.6)	1.5 (0.9-2.9)
Creatinine Phosphokinase (units/L)	237.5 (187.8-440.5)	-	156 (80-505)	-	-
Procalcitonin (ng/mL)	0.3 (0.1-0.8)	0.4 (0.2-1.4)	0.2 (0.1-0.6)	0.2 (0.1-0.5)	0.2 (0.1-0.7)
Lactate Dehydrogenase (units/L)	468 (359.5-628)	489 (390-637.5)	417 (315-559)	448 (345-651.5)	427 (324-559)
<b>Cardiac Markers</b>					
Troponin I (ng/mL)	0.2 (0.1-0.9)	-	0.1 (0.0-0.2)	-	-
<b>Outcomes</b>					
Critical	0 (0-1)	0 (0-1)	0 (0-1)	0 (0-1)	0 (0-1)
Mortality	0 (0-0)	0 (0-0)	0 (0-0)	0 (0-0)	0 (0-0)

566 **Supplementary Table 2. Baseline Patient Feature Analysis.**

567 Missingness, means, standard deviations, interquartile ranges, and histograms for all  
 568 features in the dataset.

569

Variable	Missing (N)	Present (%)	Mean	Standard Deviation	IQR - 0%	IQR - 25%	IQR - 50%	IQR - 75%	IQR - 100%	Histogram
<b>Demographics</b>										
Age	0	100%	64.5	16.5	18.3	54.4	65.7	76.5	102	
Sex	0	100%	0.581	0.494	0	0	1	1	1	
ED Admission	0	100%	0.973	0.164	0	1	1	1	1	
Other Admission Type	0	100%	0.113	0.316	0	0	0	0	1	
Never Smokers	0	100%	0.521	0.5	0	0	1	1	1	
Smoking Status: Never Asked	0	100%	0.0426	0.202	0	0	0	0	1	
Passive Smokers	0	100%	0.000982	0.0313	0	0	0	0	1	
Former Smokers	0	100%	0.205	0.403	0	0	0	0	1	
Active Smokers	0	100%	0.0383	0.192	0	0	0	0	1	
Asian	0	100%	0.0357	0.186	0	0	0	0	1	
African American	0	100%	0.254	0.435	0	0	0	1	1	
Other Race	0	100%	0.421	0.494	0	0	0	1	1	
Pacific Islander	0	100%	0.0105	0.102	0	0	0	0	1	
Unknown Race	0	100%	0.0406	0.197	0	0	0	0	1	
White	0	100%	0.238	0.426	0	0	0	0	1	
Hispanic	0	100%	0.274	0.446	0	0	0	1	1	
Non-Hispanic	0	100%	0.592	0.492	0	0	1	1	1	
Unknown Ethnicity	0	100%	0.134	0.341	0	0	0	0	1	
<b>Past Medical History</b>										

Atrial Fibrillation	0	100%	0.0707	0.256	0	0	0	0	1	
Asthma	0	100%	0.0809	0.273	0	0	0	0	1	
CAD	0	100%	0.156	0.363	0	0	0	0	1	
Cancer	0	100%	0.0674	0.251	0	0	0	0	1	
CKD	0	100%	0.0962	0.295	0	0	0	0	1	
COPD	0	100%	0.055	0.228	0	0	0	0	1	
Diabetes	0	100%	0.255	0.436	0	0	0	1	1	
Heart Failure	0	100%	0.0953	0.294	0	0	0	0	1	
Hypertension	0	100%	0.376	0.484	0	0	0	1	1	
Stroke	0	100%	0.0707	0.256	0	0	0	0	1	
<b>Vitals</b>										
Pulse	0	100%	89.5	16.7	46	78	89	100	150	
Pulse Oximetry	11	100%	95.2	3.24	76	94	96	98	99	
Respiration Rate	4	100%	20.2	4.2	7	18	19	20	46	
Temperature	6	100%	98.9	1.4	95.2	98	98.7	99.7	103	
Diastolic BP	5	100%	71.7	12.2	39	63	71	80	107	
Systolic BP	6	100%	127	21.3	72	112	126	140	189	
Weight	192	94%	82.5	20.6	40	68	79.6	93	174	
<b>Labs</b>										
ALT	111	96%	47.5	56.1	8	19	31	54	597	
AST	124	96%	64.9	73.4	13	30	44	72	905	
CRP	1901	38%	144	94.8	1.91	63.7	127	215	457	
D-Dimer	763	75%	2.53	3.15	0.28	0.79	1.43	2.75	18.8	
Ferritin	546	82%	1529	2161	36	369	776	1901	17466	
LDH	588	81%	498	261	171	328	436	585	2165	
Procalcitonin	661	78%	1.71	7.64	0.03	0.09	0.21	0.68	154	

WBC	9	100%	8.39	4.31	1.9	5.4	7.4	10.3	40	
Albumin	885	71%	2.97	0.518	1.2	2.6	3	3.3	4.1	
CPK	2768	9%	435	757	17	82.5	173	500	8103	
Creatinine	667	78%	1.73	2.22	0.37	0.74	0.97	1.55	16.1	
Hemoglobin	669	78%	12.5	2.01	6.2	11.3	12.7	13.9	17.1	
Lactate	1703	44%	1.86	1.09	0.7	1.2	1.6	2.2	9.9	
Lymphocyte (%)	871	72%	15.7	9.58	1	8.5	13.6	20.9	54.1	
PCO2	2087	32%	42.4	9.54	23	36	41	47	87	
pH	2085	32%	7.38	0.0833	7.01	7.35	7.39	7.43	7.53	
Platelets	668	78%	221	97.8	27	155	202	268	734	
Potassium	641	79%	4.21	0.684	2.9	3.7	4.1	4.6	7	
PT	2284	25%	15.4	4.25	12.2	13.5	14.3	15.6	48.1	
PTT	2293	25%	36.2	13.6	22	29.6	32.9	38	153	
RDW	688	78%	14	2.12	11.1	12.6	13.6	14.8	25.9	
Sodium	639	79%	138	5.48	123	135	138	141	163	
Bilirubin (Total)	984	68%	0.691	0.445	0.3	0.4	0.6	0.8	4.4	
Troponin-I	2605	15%	0.589	1.78	0.01	0.02	0.06	0.24	15.9	
<b>Outcomes</b>										
Critical Event	0	100%	0.166	0.372	0	0	0	0	1	
Mortality	0	100%	0.0606	0.239	0	0	0	0	1	



571 **Supplementary Table 3. Final XGBoost Model Hyperparameters.**

572 Final hyperparameters for the XGBoost classifier at day 7 for critical event and mortality  
573 prediction after tuning using a grid-search to optimize for AUC-ROC.

574

Hyperparameter	Critical outcome				Mortality			
	<i>3 Days</i>	<i>5 Days</i>	<i>7 Days</i>	<i>10 Days</i>	<i>3 Days</i>	<i>5 Days</i>	<i>7 Days</i>	<i>10 Days</i>
reg_alpha	1.0	0.10	0.01	0.1	1.0	1.0	0.1	0.1
min_child_weight	5.0	3.0	3.0	7.0	5.0	1.0	1.0	5.0
max_depth	9.0	6.0	6.0	6.0	6.0	9.0	6.0	6.0
learning_rate	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.1
gamma	0.4	0.3	0.2	0.1	0.3	0.2	0.3	0.4
colsample_bytree	0.3	0.3	0.4	0.3	0.3	0.3	0.3	0.5

575

576 **Supplementary Table 4. Model Performance Across Each Hospital.**

577 Performance of the XGBoost classifier by hospital site, as measured by accuracy  
 578 (ACC), area under the receiver operating curve (AUCROC), area under the precision  
 579 recall curve (AUCPRC), F1-score (F1), sensitivity (SENS), and specificity (SPEC). “OH”  
 580 refers to all hospitals in the external validation set (i.e. MSW, MSM, MSB, MSQ).  
 581 Outcomes are structured by “<outcome>\_<day>”, where outcome is either a critical  
 582 event (CRITICAL) or mortality (MORTALITY) and the time frame it was predicted over.  
 583 “OUTCOME PROP” refers to the portion of the dataset with the respective outcome.  
 584

FACILITY	OUTCOME	PATIENTS	PROP OUTCOME	ACC	AUCROC	AUCPRC	F1	SENS	SPEC	
<b>MSH</b>	CRITICAL_3	1225	0.17	0.90	0.89	0.71	0.59	0.84	0.90	
	CRITICAL_5	1156	0.22	0.84	0.84	0.67	0.53	0.75	0.85	
	CRITICAL_7	1052	0.25	0.81	0.83	0.66	0.53	0.71	0.83	
	CRITICAL_10	931	0.28	0.80	0.83	0.67	0.57	0.70	0.82	
	MORTALITY_3	1225	0.03	0.97	0.87	0.26	0.03	1.00	0.97	
	MORTALITY_5	1156	0.05	0.95	0.84	0.37	0.13	0.56	0.95	
	MORTALITY_7	1052	0.07	0.93	0.87	0.49	0.21	0.71	0.94	
	MORTALITY_10	931	0.12	0.90	0.84	0.50	0.36	0.65	0.91	
	<b>MSQ</b>	CRITICAL_3	459	0.20	0.81	0.79	0.52	0.21	0.60	0.82
		CRITICAL_5	440	0.29	0.73	0.79	0.59	0.21	0.67	0.73
CRITICAL_7		414	0.36	0.69	0.77	0.65	0.31	0.71	0.68	
CRITICAL_10		390	0.41	0.69	0.80	0.73	0.46	0.80	0.67	
MORTALITY_3		459	0.14	0.86	0.77	0.42	0.00	-	0.86	
MORTALITY_5		440	0.23	0.80	0.76	0.56	0.21	0.92	0.79	
MORTALITY_7		414	0.30	0.74	0.77	0.61	0.25	0.86	0.73	
MORTALITY_10		390	0.37	0.68	0.78	0.67	0.29	0.74	0.67	
<b>MSB</b>		CRITICAL_3	460	0.17	0.85	0.77	0.45	0.20	0.75	0.85
		CRITICAL_5	426	0.28	0.75	0.80	0.63	0.19	0.93	0.74
	CRITICAL_7	397	0.35	0.68	0.76	0.61	0.17	0.81	0.67	
	CRITICAL_10	370	0.41	0.65	0.80	0.71	0.32	0.79	0.63	
	MORTALITY_3	460	0.10	0.90	0.79	0.39	0.04	1.00	0.90	
	MORTALITY_5	426	0.21	0.80	0.83	0.58	0.11	1.00	0.80	
	MORTALITY_7	397	0.28	0.75	0.82	0.66	0.22	1.00	0.74	
	MORTALITY_10	370	0.36	0.67	0.79	0.67	0.19	0.88	0.66	
	<b>MSW</b>	CRITICAL_3	351	0.12	0.89	0.81	0.46	0.31	0.53	0.90
		CRITICAL_5	331	0.15	0.86	0.78	0.45	0.43	0.57	0.89
CRITICAL_7		307	0.16	0.87	0.81	0.52	0.44	0.64	0.89	
CRITICAL_10		280	0.20	0.83	0.80	0.58	0.49	0.59	0.87	
MORTALITY_3		351	0.02	0.98	0.89	0.09	0.00	-	0.98	
MORTALITY_5		331	0.03	0.97	0.86	0.23	0.00	-	0.97	
MORTALITY_7		307	0.05	0.95	0.88	0.38	0.00	0.00	0.95	

	MORTALITY_10	280	0.07	0.95	0.80	0.41	0.40	1.00	0.95
<b>MSM</b>	CRITICAL_3	560	0.16	0.82	0.73	0.34	0.20	0.36	0.85
	CRITICAL_5	525	0.22	0.78	0.73	0.41	0.30	0.50	0.81
	CRITICAL_7	481	0.26	0.76	0.75	0.50	0.34	0.63	0.78
	CRITICAL_10	420	0.32	0.75	0.78	0.64	0.50	0.68	0.76
	MORTALITY_3	560	0.06	0.94	0.89	0.43	0.00	-	0.94
	MORTALITY_5	525	0.10	0.90	0.87	0.48	0.04	1.00	0.90
	MORTALITY_7	481	0.14	0.87	0.84	0.49	0.14	1.00	0.87
	MORTALITY_10	420	0.20	0.84	0.84	0.61	0.34	0.82	0.84
<b>OH</b>	CRITICAL_3	1830	0.17	0.84	0.77	0.43	0.23	0.57	0.85
	CRITICAL_5	1722	0.24	0.78	0.76	0.51	0.26	0.65	0.79
	CRITICAL_7	1599	0.29	0.73	0.74	0.52	0.30	0.60	0.75
	CRITICAL_10	1460	0.34	0.73	0.79	0.66	0.44	0.77	0.73
	MORTALITY_3	1830	0.08	0.92	0.83	0.38	0.03	1.00	0.92
	MORTALITY_5	1722	0.15	0.86	0.82	0.52	0.08	1.00	0.86
	MORTALITY_7	1599	0.20	0.82	0.84	0.58	0.18	0.86	0.82
	MORTALITY_10	1460	0.26	0.79	0.83	0.64	0.40	0.74	0.79

585  
586

587

588 **Supplementary Table 5. Model Performance At Extended Time Frames.**

589 Performance of the XGBoost classifier on validation set from MSH and external  
590 validation set (MSB, MSW, MSQ, MSM), as measured by accuracy (ACC), area under  
591 the receiver operating curve (AUCROC), area under the precision recall curve  
592 (AUCPRC), F1-score (F1), sensitivity (SENS), and specificity (SPEC). “OH” refers to all  
593 hospitals in the external validation set (i.e. MSW, MSM, MSB, MSQ). Outcomes are  
594 structured by “<outcome>\_<day>”, where outcome is either a critical event (CRITICAL)  
595 or mortality (MORTALITY) and the time frame it was predicted over. “OUTCOME  
596 PROP” refers to the portion of the dataset with the respective outcome.  
597

FACILITY	OUTCOME	PATIENTS	PROP OUTCOME	ACC	AUCROC	AUCPRC	F1	SENS	SPEC
<b>MSH</b>	CRITICAL_15	792	0.27	0.81	0.84	0.68	0.60	0.71	0.84
	CRITICAL_20	719	0.25	0.82	0.85	0.68	0.58	0.70	0.85
	MORTALITY_15	792	0.16	0.87	0.86	0.58	0.58	0.64	0.89
	MORTALITY_20	719	0.18	0.86	0.87	0.64	0.54	0.67	0.87
<b>OH</b>	CRITICAL_15	1320	0.37	0.72	0.75	0.66	0.53	0.68	0.73
	CRITICAL_20	1254	0.36	0.75	0.81	0.71	0.57	0.75	0.75
	MORTALITY_15	1320	0.32	0.74	0.81	0.65	0.40	0.75	0.74
	MORTALITY_20	1254	0.34	0.75	0.84	0.72	0.51	0.77	0.75

598

599

600

601 **Supplementary Table 6. Logistic Regression and Generalized Additive Model**  
602 **Performance.**

603 Performance of the four models using only Age and all the features, as measured by  
604 accuracy (ACC), area under the receiver operating curve (AUCROC), area under the  
605 precision recall curve (AUCPRC), F1-score (F1), sensitivity (SENS), and specificity  
606 (SPEC). Models are structured by “<model>\_<feature space>”, where model is either a  
607 logistic regression (LOG) or generalized additive model (GAM) and the features used in  
608 the model.

MODEL	OUTCOME	PATIENTS	PROP OUTCOME	ACC	AUCROC	AUCPRC	F1	SENS	SPEC
<b>LOG_AGE</b>	CRITICAL_3	3055	0.17	0.83	0.57	0.22	0	1	0
	MORTALITY_3	3055	0.06	0.92	0.70	0.18	0	1	0
<b>GAM_AGE</b>	CRITICAL_3	3055	0.17	0.83	0.52	0.19	0.01	1	0.003
	MORTALITY_3	3055	0.06	0.98	0.62	0.14	0	1	0
<b>LOG_ALL</b>	CRITICAL_3	1278	0.18	0.81	0.74	0.33	0.31	0.90	0.29
	MORTALITY_3	1278	0.02	0.96	0.67	0.06	0.07	0.98	0.07
<b>GAM_ALL</b>	CRITICAL_3	1278	0.18	0.82	0.74	0.37	0.35	0.92	0.31
	MORTALITY_3	1278	0.02	0.98	0.62	0.14	0	1	0

609